Nothing Special   »   [go: up one dir, main page]

MX2019013308A - Composiciones y compuestos terapeuticos, y metodos para su uso. - Google Patents

Composiciones y compuestos terapeuticos, y metodos para su uso.

Info

Publication number
MX2019013308A
MX2019013308A MX2019013308A MX2019013308A MX2019013308A MX 2019013308 A MX2019013308 A MX 2019013308A MX 2019013308 A MX2019013308 A MX 2019013308A MX 2019013308 A MX2019013308 A MX 2019013308A MX 2019013308 A MX2019013308 A MX 2019013308A
Authority
MX
Mexico
Prior art keywords
methods
compositions
therapeutic compounds
jak
compounds
Prior art date
Application number
MX2019013308A
Other languages
English (en)
Inventor
Zak Mark
Xing Cheng Yun-
Anthony Romero F
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2019013308A publication Critical patent/MX2019013308A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Los compuestos y las sales de estos que son útiles como inhibidores de JAK cinasa se describen en la presente. También se proporcionan composiciones farmacéuticas que incluyen tal inhibidor JAK y un portador, adyuvante o vehículo farmacéuticamente aceptable, y métodos para tratar o aminorar la gravedad de una enfermedad o afección que responde a la inhibición de una actividad de Janus cinasa en un paciente.
MX2019013308A 2017-05-22 2018-05-21 Composiciones y compuestos terapeuticos, y metodos para su uso. MX2019013308A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2017085276 2017-05-22
US201862640865P 2018-03-09 2018-03-09
PCT/EP2018/063262 WO2018215389A1 (en) 2017-05-22 2018-05-21 Therapeutic compounds and compositions, and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2019013308A true MX2019013308A (es) 2020-02-12

Family

ID=62386421

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019013308A MX2019013308A (es) 2017-05-22 2018-05-21 Composiciones y compuestos terapeuticos, y metodos para su uso.

Country Status (19)

Country Link
US (3) US10307426B2 (es)
EP (1) EP3630766A1 (es)
JP (2) JP7256757B2 (es)
KR (1) KR20200010390A (es)
CN (1) CN110650959B (es)
AU (1) AU2018274577A1 (es)
BR (1) BR112019024322A2 (es)
CA (1) CA3061236A1 (es)
CL (1) CL2019003258A1 (es)
CO (1) CO2019010559A2 (es)
CR (1) CR20190520A (es)
MA (1) MA48942A (es)
MX (1) MX2019013308A (es)
PE (1) PE20200341A1 (es)
PH (1) PH12019502601A1 (es)
RU (1) RU2769696C2 (es)
SG (1) SG11201909735YA (es)
TW (1) TW201902896A (es)
WO (1) WO2018215389A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3061236A1 (en) * 2017-05-22 2018-11-29 F. Hoffmann-La Roche Ag Therapeutic compounds and compositions, and methods of use thereof
AU2020242287A1 (en) 2019-03-21 2021-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) A Dbait molecule in combination with kinase inhibitor for the treatment of cancer
PE20220577A1 (es) 2019-06-18 2022-04-20 Hoffmann La Roche Inhibidores de jak cinasas basados en pirazolopirimidina sulfona y usos de los mismos
EP3986899A1 (en) * 2019-06-18 2022-04-27 F. Hoffmann-La Roche AG Pyrazolopyrimidine aryl ether inhibitors of jak kinases and uses thereof
JP7039045B2 (ja) * 2019-08-26 2022-03-22 株式会社フェニックスバイオ ヒト脂肪肝モデル細胞
CN114761006A (zh) 2019-11-08 2022-07-15 Inserm(法国国家健康医学研究院) 对激酶抑制剂产生耐药性的癌症的治疗方法
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES517193A0 (es) 1981-11-10 1983-12-01 Wellcome Found Un procedimiento para la preparacion de nuevos derivados de imidazo (4,5-c)piridina.
US4847256A (en) 1986-10-16 1989-07-11 American Cyanamid Company 4,5-dihydro and 4,5,6,7-tetrahydropyrazolo(1,5-A)-pyrimidines
AU650953B2 (en) 1991-03-21 1994-07-07 Novartis Ag Inhaler
US5728536A (en) 1993-07-29 1998-03-17 St. Jude Children's Research Hospital Jak kinases and regulation of Cytokine signal transduction
US6136595A (en) 1993-07-29 2000-10-24 St. Jude Children's Research Hospital Jak kinases and regulations of cytokine signal transduction
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
US5705625A (en) 1994-12-15 1998-01-06 The Johns Hopkins University School Of Medicine Nucleic Acid Encoding novel protein tyrosine kinase
US7070972B1 (en) 1995-01-13 2006-07-04 The United States Of America As Represented By The Department Of Health And Human Services Janus family kinases and identification of immune modulators
US6034057A (en) 1995-07-06 2000-03-07 Zeneca Limited Peptide inhibitors of fibronectine
US6248713B1 (en) 1995-07-11 2001-06-19 Biogen, Inc. Cell adhesion inhibitors
US7091020B1 (en) 1995-12-05 2006-08-15 Incyte Corporation Human Jak2 kinase
ID18494A (id) 1996-10-02 1998-04-16 Novartis Ag Turunan pirazola leburan dan proses pembuatannya
US6235741B1 (en) 1997-05-30 2001-05-22 Merck & Co., Inc. Angiogenesis inhibitors
FR2791562B1 (fr) 1999-03-29 2004-03-05 Oreal Composition tinctoriale contenant une pyrazolo-[1,5-a]- pyrimidine et une polyaminopyrimidine monocyclique a titre de bases d'oxydation et un coupleur, et procedes de teinture
YU25500A (sh) 1999-05-11 2003-08-29 Pfizer Products Inc. Postupak za sintezu analoga nukleozida
ATE303387T1 (de) 1999-07-02 2005-09-15 Eisai Co Ltd Kondensierte imidazolderivate und arzneimittel gegen diabetes mellitus
OA12118A (en) 1999-12-10 2006-05-04 Pfizer Prod Inc PyrroloÄ2,3-dÜpyrimidine compounds.
GB0028383D0 (en) 2000-11-21 2001-01-03 Novartis Ag Organic compounds
EP1241176A1 (en) 2001-03-16 2002-09-18 Pfizer Products Inc. Purine derivatives for the treatment of ischemia
AU2002361992A1 (en) 2001-12-20 2003-07-09 Bayer Aktiengesellschaft 1,4-dihydro-1,4-diphenylpyridine derivatives
AU2003227437A1 (en) 2002-04-23 2003-11-10 Shionogi And Co., Ltd. PYRAZOLO(1,5-a)PYRIMIDINE DERIVATIVE AND NAD(P)H OXIDASE INHIBITOR CONTAINING THE SAME
US7161003B1 (en) 2002-09-04 2007-01-09 Schering Corporation Pyrazolopyrimidines as cyclin dependent kinase inhibitors
US8580782B2 (en) 2002-09-04 2013-11-12 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
US7129239B2 (en) 2002-10-28 2006-10-31 Pfizer Inc. Purine compounds and uses thereof
WO2004041285A1 (en) 2002-10-31 2004-05-21 Amgen Inc. Antiinflammation agents
AU2003299651A1 (en) 2002-12-11 2004-06-30 Merck And Co., Inc. Tyrosine kinase inhibitors
WO2004089471A2 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S NEW PYRAZOLO[1,5-a] PYRIMIDINES DERIVATIVES AND PHARMACEUTICAL USE THEREOF
US20070270408A1 (en) 2003-04-11 2007-11-22 Novo Nordisk A/S Pharmaceutical use of substituted pyrazolo[1,5-a]pyrimidines
WO2004089415A2 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S COMBINATIONS OF AN 11β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITOR AND A GLUCOCORTICOID RECEPTOR AGONIST
WO2004089416A2 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S Combination of an 11beta-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent
WO2005004810A2 (en) 2003-07-02 2005-01-20 Merck & Co., Inc. Arylsulfonamide derivatives
TWI372050B (en) 2003-07-03 2012-09-11 Astex Therapeutics Ltd (morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
SE0302487D0 (sv) 2003-09-18 2003-09-18 Astrazeneca Ab Novel compounds
GB0329214D0 (en) 2003-12-17 2004-01-21 Glaxo Group Ltd Novel compounds
US7306631B2 (en) 2004-03-30 2007-12-11 The Procter & Gamble Company Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof
WO2005110477A2 (en) 2004-04-09 2005-11-24 University Of South Florida Combination therapies for cancer and proliferative angiopathies
CA2565037A1 (en) 2004-04-28 2005-11-10 Cv Therapeutics, Inc. Purine derivatives as a1 adenosine receptor antagonists
CA2570319A1 (en) 2004-06-25 2006-01-12 Amgen Inc. Condensed triazoles and indazoles useful in treating citokines mediated diseases and other diseases
KR20070090172A (ko) 2004-11-04 2007-09-05 버텍스 파마슈티칼스 인코포레이티드 단백질 키나아제의 억제제로서 유용한피라졸로[1,5-ａ]피리미딘
GB0502258D0 (en) 2005-02-03 2005-03-09 Argenta Discovery Ltd Compounds and their use
WO2007013673A1 (en) 2005-07-29 2007-02-01 Astellas Pharma Inc. Fused heterocycles as lck inhibitors
WO2007039797A1 (en) 2005-10-03 2007-04-12 Pfizer Products Inc. Use of cannabinoid receptor-1 antagonist for treating inflammation and arthritis
CA2624500A1 (en) 2005-10-06 2007-04-19 Schering Corporation Pyrazolopyrimidines as protein kinase inhibitors
BRPI0617150A2 (pt) * 2005-10-06 2011-07-12 Schering Corp pirazolopirimidinas como inibidores de protéina cinase
WO2007048064A2 (en) 2005-10-21 2007-04-26 Exelixis, Inc. Amino-pyrimidines as casein kinase ii (ck2) modulators
JP2009518340A (ja) 2005-12-08 2009-05-07 ノバルティス アクチエンゲゼルシャフト ＥｐｈＢおよびＶＥＧＦＲ２キナーゼ阻害剤としてのピラゾロ［１，５−ａ］ピリジン−３−カルボン酸
US8541406B2 (en) 2006-02-07 2013-09-24 Nv Remynd Thiadiazole derivatives for the treatment of neurodegenerative diseases
TW200800997A (en) 2006-03-22 2008-01-01 Astrazeneca Ab Chemical compounds
AR061793A1 (es) 2006-07-05 2008-09-24 Mitsubishi Tanabe Pharma Corp Compuesto de pirazolo[1,5-a] pirimidina y composicion farmaceutica
PE20121506A1 (es) 2006-07-14 2012-11-26 Amgen Inc Compuestos triazolopiridinas como inhibidores de c-met
US8217177B2 (en) 2006-07-14 2012-07-10 Amgen Inc. Fused heterocyclic derivatives and methods of use
CA2667962A1 (en) 2006-10-30 2008-05-08 Novartis Ag Heterocyclic compounds as antiinflammatory agents
WO2008063671A2 (en) 2006-11-20 2008-05-29 Alantos Pharmaceuticals Holding, Inc. Heterobicyclic metalloprotease inhibitors
WO2009017954A1 (en) 2007-08-01 2009-02-05 Phenomix Corporation Inhibitors of jak2 kinase
NZ584454A (en) 2007-10-12 2011-09-30 Ingenium Pharmaceuticals Gmbh N-[6-phenyl-pyrimidin-4-yl]-amides and urea derivatives as inhibitors of protein kinases
CN104311563B (zh) 2007-11-28 2016-12-07 达那-法伯癌症研究所 Bcr-abl的小分子豆蔻酸酯抑制剂及其使用方法
EP2219646A4 (en) 2007-12-21 2010-12-22 Univ Rochester METHOD FOR MODIFYING THE LIFETIME OF EUKARYOTIC ORGANISMS
US20100048557A1 (en) 2008-06-20 2010-02-25 Bing-Yan Zhu Triazolopyridine JAK Inhibitor Compounds and Methods
WO2010019762A1 (en) 2008-08-13 2010-02-18 Jenrin Discovery Purine compounds as cannabinoid receptor blockers
ES2545541T3 (es) * 2008-10-31 2015-09-11 Genentech, Inc. Compuestos de pirazolopirimidina inhibidores de JAK y métodos
WO2010063487A1 (en) 2008-12-05 2010-06-10 Merz Pharma Gmbh & Co. Kgaa Pyrazolopyrimidines, a process for their preparation and their use as medicine
EA019685B1 (ru) 2009-02-06 2014-05-30 Янссен Фармасьютикалз, Инк. Новые замещенные бициклические гетероциклические соединения в качестве модуляторов гамма-секретазы
TWI461425B (zh) 2009-02-19 2014-11-21 Janssen Pharmaceuticals Inc 作為伽瑪分泌酶調節劑之新穎經取代的苯并唑、苯并咪唑、唑并吡啶及咪唑并吡啶衍生物類
UA110324C2 (en) 2009-07-02 2015-12-25 Genentech Inc Jak inhibitory compounds based on pyrazolo pyrimidine
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
US9242987B2 (en) 2009-10-20 2016-01-26 Cellzome Limited Heterocyclyl pyrazolopyrimidine analogues as JAK inhibitors
EP2547338A2 (en) 2010-03-17 2013-01-23 F. Hoffmann-La Roche AG Imidazopyridine compounds, compositions and methods of use
WO2011134831A1 (en) 2010-04-30 2011-11-03 Cellzome Limited Pyrazole compounds as jak inhibitors
JP5985473B2 (ja) 2010-07-13 2016-09-06 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ＩＲＡＫ４モジュレーターとしてのピラゾロ［１，５ａ］ピリミジン及びチエノ［３，２ｂ］ピリミジン誘導体
WO2012075393A2 (en) 2010-12-02 2012-06-07 President And Fellows Of Harvard College Activators of proteasomal degradation and uses thereof
EP2688872A4 (en) * 2011-03-22 2014-08-27 Merck Sharp & Dohme AMIDOPYRAZOLHEMMER OF INTERLEUKIN RECEPTOR-MEDIATED KINASES
US8575336B2 (en) 2011-07-27 2013-11-05 Pfizer Limited Indazoles
ES2666353T3 (es) 2012-09-06 2018-05-04 Bristol-Myers Squibb Company Inhibidores de JAK3 de imidazopiridazina y su uso para el tratamiento de enfermedades inflamatorias y autoinmunitarias
PT2917181T (pt) 2012-11-09 2020-01-08 Medicines For Malaria Venture Mmv Derivados de heteroarilo e suas utilizações
US20160166576A1 (en) 2013-07-11 2016-06-16 Merck Sharp & Dohme Corp. Substituted amidopyrazole inhibitors of interleukin receptor-associated kinases (irak-4)
BR112016010041B1 (pt) 2013-11-08 2023-04-18 Takeda Pharmaceutical Company Limited Composto heterocíclico com uma ação inibitória de irak-4, composição farmacêutica, e, uso do composto
WO2015073267A1 (en) 2013-11-15 2015-05-21 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
TWI699364B (zh) * 2014-05-23 2020-07-21 瑞士商赫孚孟拉羅股份公司 ５-氯-２-二氟甲氧基苯基吡唑并嘧啶化合物、組合物及其使用方法
MX2016015326A (es) 2014-05-23 2017-05-30 Phibro Animal Health Corporation Combinacion, composicion y metodo de administracion de la combinacion o composicion a animales.
JO3701B1 (ar) 2014-05-23 2021-01-31 Regeneron Pharma مضادات حيوية بشرية لمتلازمة الشرق الأوسط التنفسية - بروتين كورونا فيروس الشوكي
ES2984482T3 (es) 2014-11-06 2024-10-29 Bial R&D Invest S A Pirazolo[1,5-a]pirimidinas sustituidas y su uso en el tratamiento de trastornos médicos
EP3268367B8 (en) 2015-03-12 2022-11-16 Merck Sharp & Dohme LLC Carboxamide inhibitors of irak4 activity
EP3268004B1 (en) 2015-03-12 2019-12-18 Merck Sharp & Dohme Corp. Pyrrolopyridazine inhibitors of irak4 activity
WO2016144848A1 (en) 2015-03-12 2016-09-15 Merck Sharp & Dohme Corp. Pyrrolotriazine inhibitors of irak4 activity
WO2016144846A1 (en) 2015-03-12 2016-09-15 Merck Sharp & Dohme Corp. Pyrazolopyrimidine inhibitors of irak4 activity
TW201720828A (zh) 2015-11-23 2017-06-16 赫孚孟拉羅股份公司 治療性化合物及組合物以及其使用方法
CN108473501B (zh) 2016-02-18 2021-07-16 豪夫迈·罗氏有限公司 治疗化合物、其组合物及使用方法
CN110114343B (zh) 2016-12-29 2022-09-06 豪夫迈·罗氏有限公司 吡唑并嘧啶化合物及其使用方法
JP2020510061A (ja) 2017-03-14 2020-04-02 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ピラゾロクロロフェニル化合物、組成物及びその使用方法
JP7228318B6 (ja) 2017-05-22 2023-03-10 エフ． ホフマン－ラ ロシュ アーゲー 処置用化合物及び組成物、並びにその使用方法
CA3061236A1 (en) * 2017-05-22 2018-11-29 F. Hoffmann-La Roche Ag Therapeutic compounds and compositions, and methods of use thereof

Also Published As

Publication number Publication date
EP3630766A1 (en) 2020-04-08
US20200352951A1 (en) 2020-11-12
RU2019141734A (ru) 2021-06-23
CL2019003258A1 (es) 2020-04-17
WO2018215389A1 (en) 2018-11-29
MA48942A (fr) 2020-04-08
PE20200341A1 (es) 2020-02-14
BR112019024322A2 (pt) 2020-06-16
US20180333416A1 (en) 2018-11-22
JP7256757B2 (ja) 2023-04-12
JP2023058657A (ja) 2023-04-25
PH12019502601A1 (en) 2020-06-08
CO2019010559A2 (es) 2019-10-09
CA3061236A1 (en) 2018-11-29
CR20190520A (es) 2020-01-21
RU2019141734A3 (es) 2021-08-10
RU2769696C2 (ru) 2022-04-05
KR20200010390A (ko) 2020-01-30
AU2018274577A1 (en) 2019-10-10
CN110650959A (zh) 2020-01-03
US20190240227A1 (en) 2019-08-08
TW201902896A (zh) 2019-01-16
CN110650959B (zh) 2023-04-18
JP2020520959A (ja) 2020-07-16
US10307426B2 (en) 2019-06-04
SG11201909735YA (en) 2019-11-28

Similar Documents

Publication Publication Date Title
PH12019502601A1 (en) Therapeutic compounds and compositions, and methods of use thereof
MX2022007915A (es) Compuestos de benzopirazol y analogos de estos.
WO2017089390A8 (en) Janus kinases inhibitors, compositions thereof and use thereof
MD4800C1 (ro) Compuşi de aminopirimidinil ca inhibitori de JAK
MX2017013797A (es) Inhibidor de janus quinasa.
PH12016501750A1 (en) Human plasma kallikrein inhibitors
WO2016044556A3 (en) Arginine methyltransferase inhibitors and uses thereof
MX2021004639A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos.
MX2015008957A (es) Fluoro-[1,3]oxazinas como inhibidores de beta-secretasa 1 (bace1).
MX2017000806A (es) Derivados de 2-h-indazol como inhibidores de kinasas dependientes de ciclinas (cdk) y usos terapeuticos de los mismos.
WO2016109217A3 (en) Btk inhibitors
SA519402103B1 (ar) 1,6-naphthyridine مشتقات 1، 6 نفثيرايدين CDK4/6 على شكل مثبط
MX2017012123A (es) Combinaciones de un compuesto inhibidor de fosfoinositido 3-cinasa y un compuesto inhibidor de cdk4/6 para el tratamiento del cancer.
MX2021010297A (es) Inhibidores de calicreina plasmatica humana.
EP4234021A3 (en) Pharmaceutical composition comprising an adenosine derivative for use in the prevention or treatment of diabetic nephropathy
PH12018500096A1 (en) Mdm2 inhibitors for treating uveal melanoma
PH12021550143A1 (en) Pyridopyrimidines as histamine h4-receptor inhibitors
PH12017501668A1 (en) Bace1 inhibitors
CR20210661A (es) Inhibidores de jak cinasas basados en pirazolopirimidina sulfona y usos de los mismos
NZ738247A (en) 4-(3-pyrazolylamino)-benzimidazole compounds and their use as jak1 inhibitors
WO2018057808A8 (en) Benzimidazole derivatives and their use as phosphatidylinositol 3-kinase inhibitors
MX2019014773A (es) Inhibidores de ccl2.
IL260274A (en) Use of inhibitors of pi3k activity or function to treat primary Sjogren's syndrome
MY192305A (en) Bipyrazole derivatives as jak inhibitors